Efficacy and risks of artificial intelligence chatbots for anxiety and depression: a narrative review of recent clinical studies.

Rebekah Bodner¹, Katherine Lim¹, Renee Schneider^1,2, John Torous¹

¹Beth Israel Deaconess Medical Center, Division of Digital Psychiatry, Harvard Medical School.

²Google Health, Google Research, New York, New York, USA.

Abstract

PURPOSE OF REVIEW: The rapidly growing environment of artificial intelligence (AI) has accelerated interest in its potential use for improving the efficiency and efficacy of the healthcare industry. Specifically, there has been a growing interest in AI role mental healthcare for common disorders like anxiety and depression. However, it remains unclear whether current evidence is sufficient to dete…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.